Archived News
In August 2021 Finfeed changed from a website that covered ASX listed news to a website
that covered a select range of ASX
listed small cap Biotech stocks that we are personally
invested in: find out more.
The old Finfeed website, and all of the old articles are kept here for record keeping purposes.
VISIT NEW SITEEtherstack signs NEC Corporation licensing deal
1 minute read
Critical radio technologies company Etherstack (ASX:ESK) has signed a substantial licensing contract with technology company NEC Corporation.
Through the deal ESK’s wireless technology will be incorporated into NEC’s products.
NEC is a leader in the integration of IT and network technologies, having been in business for over 100 years.
The contract is expected to add 60 million Japanese Yen (A$770,000) to ESK’s 2016 revenues.
ESK’s R&D centre based in Yokohama that has been in operation for over 10 years and will provide local support to NEC.
The technology itself will be delivered to NEC by ESK’s multinational team of engineers.
ESK CEO David Deacon notes that by integrating tried and tested ESK technology, NEC will be able to de-risk and accelerate delivery of sophisticated radio systems.
Full year revenue guidance for ESK in 2016 is set to be between US$5.8M and US$6.1M.
ESK having earned in excess of $100m in revenues since 2007.
However this should not be used as a projection of future revenues or profit. Please seek professional financial advice before making any investment decision.
Latest articles on Etherstack
More Commentary
FYI establishes ties with independent ESG reporting platform
01-07-2021
Australian Government Awards FYI National Project Status
29-06-2021
AHI and Nexus-Vita to fast track integration
22-06-2021
Oneview signs long-term contract with a second Victorian hospital
18-06-2021S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
Publishers Notice
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain.